Diurnal Group plc (DNL) Ordinary 5p
0.50p
(1.69%)
- Add to watchlist
- Create an alert
- This stock can be held in a
0.50p
(1.69%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA,
SIPP or
Fund and Share Account
0.50p
(1.69%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA,
SIPP or
Fund and Share Account
Share news, reports & tips
-
Diurnal submits application for 'Alkindi Sprinkle' to US FDA
2 December 2019 13:19
(Sharecast News) - Specialty pharmaceutical company Diurnal Group has submitted a 'New Drug Application' (NDA) to the US Food and Drug Administration (FDA), for the regulatory approval of...
-
Diurnal partner submits marketing authorisation for \'Alkindi\' in Australia
3 July 2019 10:38
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Wednesday that an application for market authorisation for \'Alkindi\' - hydrocortisone granules in capsules for...
-
Diurnal Group launches placing and open offer to fund drug development
28 May 2019 13:32
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to...
-
Diurnal gets orphan drug designation for Alkindi in Australia
24 April 2019 15:50
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that its 'Alkindi' product - hydrocortisone granules in capsules for opening - had been granted orphan drug...
-
Diurnal soars after securing Nordic distribution deal
28 March 2019 08:35
(Sharecast News) - Diurnal's shares leapt on Thursday despite a widened interim loss as the company landed a marketing and distribution deal for its Alkindi treatment in Scandinavia.
-
Diurnal Group upbeat following FDA meeting over 'Alkindi'
20 March 2019 10:33
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that, following a "positive" meeting with the US Food and Drug Administration (FDA), it intended to submit a...
-
Diurnal expecting Israel launch of 'Alkindi' next year
25 February 2019 10:39
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Monday that its marketing and distribution partner, Medison Pharma has successfully submitted a market authorisation application...
-
Diurnal awarded US patent for Chronocort product
10 January 2019 11:26
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Thursday that the US Patent and Trademark Office (USPTO) has granted a second US patent for its 'Chronocort' modified...
-
Diurnal halts US development of Chronocort after European trials come up short
17 October 2018 12:10
(Sharecast News) - Speciality pharmaceutical company Diurnal has put all development activities for its modified release hydrocortisone product on hold after it failed to meet its primary endpoint in a...
-
Diurnal's endocrine drug does not meet trial objective
8 October 2018 09:29
(Sharecast News) - Clinical trials of Diurnal Group's Chronocort drug failed to meet the primary objective of proving superior to conventional therapy in endocrine control over a 24-hour period.
-
Diurnal kicks off adrenal condition trial with first patients
5 October 2018 09:20
(Sharecast News) - Specialist pharmaceutical company Diurnal said it had enrolled the first two patients in its US-based Chronocort phase III trial for adults with congenital adrenal hyperplasia (CAH).
-
Diurnal launches paediatric adrenal treatment in Germany
15 May 2018 09:16
(Sharecast News) - Pharmaceutical firm Diurnal announced on Tuesday that it has launched its Alkindi product in Germany following the grant of European marketing authorisation in February.
Company announcements Announcements
-
Share Option Exercise and Issue of Equity
2 December 2019 14:28
Diurnal Group
-
Holding(s) in Company
2 December 2019 07:01
Diurnal Group
-
Alkindi New Drug Application Submitted to US FDA
2 December 2019 07:00
Diurnal Group
-
Director Dealings and Issue of Equity
26 November 2019 10:42
Diurnal Group
-
Hardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
26 November 2019 07:15
Diurnal Group
-
Results of Annual General Meeting
21 November 2019 13:08
Diurnal Group
-
AGM Statement
21 November 2019 07:00
Diurnal Group
-
Successful outcome of testosterone clinical study
20 November 2019 07:00
Diurnal Group
-
Vesting of LTIP awards
8 November 2019 07:00
Diurnal Group
-
Hardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
5 November 2019 07:30
Diurnal Group
-
Issue of Equity
21 October 2019 18:23
Diurnal Group
-
Director Dealings
21 October 2019 13:09
Diurnal Group
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see http://www.DigitalLook.com/newsfeedterms for our terms and conditions.
© Digital Look Ltd 1998-2019. All rights reserved.
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA,
SIPP or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.